Known targets — ChEMBL curated mechanism
ADRB1ADRB2ATP4AATP4BAXLCHRM2CHRM3DRD2FLT3HRH1HTR2AHTR2BHTR2CKCNH2KMT2AMAP2K1MAP2K2MEN1MLNRPLK4RENS1PR1SLC6A2SLC6A4atpAatpBatpCatpDatpEatpFatpFHatpGpol
The experimentally established mechanism targets of Fumaric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 known ✓ | P14416 | 2/20 | 0.53 |
| ▸ | MEN1 known ✓ | O00255 | 1/20 | 0.43 |
| ▸ | HTR2A known ✓ | P28223 | 1/20 | 0.43 |
| ▸ | HTR2C known ✓ | P28335 | 1/20 | 0.43 |
| ▸ | KMT2A known ✓ | Q03164 | 1/20 | 0.43 |
| ▸ | HTR7 | P34969 | 2/20 | 0.53 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.53 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.53 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.53 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.53 |
| ▸ | USP2 | O75604 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | DRD1 | P21728 | 2/20 | 0.53 |
| ▸ | DRD5 | P21918 | 2/20 | 0.53 |
| ▸ | DRD3 | P35462 | 2/20 | 0.53 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fumaric Acid SCHEMBL25201865 | 1.00 | HTR7 (0.53) | HTR7ADRA2AADRA2BADRA2CNISCH | |
| SCHEMBL29564708 | 0.89 | CYP2D6 (0.64) | HTR7ADRA2AADRA2BADRA2CNISCH | |
| SCHEMBL25192385 | 0.89 | CYP2D6 (0.64) | HTR7ADRA2AADRA2BADRA2CNISCH | |
| SCHEMBL25192202 | 0.81 | CYP2D6 (0.53) | HTR7ADRA2AADRA2BADRA2CNISCH | |
| SCHEMBL25183522 | 0.81 | HTR7 (0.56) | HTR7ADRA2AADRA2BADRA2CNISCH | |
| SCHEMBL18034945 | 0.80 | CYP2D6 (0.62) | HTR7ADRA2AADRA2BADRA2CNISCH | |
| SCHEMBL28465408 | 0.78 | BAZ2B (0.67) | HTR7ADRA2AADRA2BADRA2CNISCH | |
| SCHEMBL25190777 | 0.78 | HTR7 (0.56) | HTR7ADRA2AADRA2BADRA2CNISCH | |
| SCHEMBL25634012 | 0.77 | DRD2 (0.52) | HTR7ADRA2AADRA2BADRA2CNISCH | |
| SCHEMBL25774052 | 0.76 | HTR7 (0.54) | HTR7ADRA2AADRA2BADRA2CNISCH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11905295-B2 | Solid forms of tabernanthalog monofumarate salt for treating neurological disorders and/or psychiatric disorders | TERRAN BIOSCIENCES INC. (US) | 2024-02-20 | — | — | US | disclosed |
| US-20230279017-A1 | SALT AND SOLID FORMS OF TABERNANTHALOG | TERRAN BIOSCIENCES INC. | 2023-09-07 | — | — | US | disclosed |
| US-20230257385-A1 | SALT AND SOLID FORMS OF TABERNANTHALOG | TERRAN BIOSCIENCES INC (US) | 2023-08-17 | — | — | US | disclosed |
| WO-2023092045-A1 | SALT AND SOLID FORMS OF TABERNANTHALOG | TERRAN BIOSCIENCES, INC. (US) | 2023-05-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230257385-A1 | SALT AND SOLID FORMS OF TABERNANTHALOG | SLC6A2, SLC6A4, SLC6A3 | DRD2 2397/4885MEN1 2739/4885HTR2A 794/4885 |
| US-20230279017-A1 | SALT AND SOLID FORMS OF TABERNANTHALOG | SLC6A2, SLC6A4, SLC6A3 | DRD2 2397/4885MEN1 2739/4885HTR2A 794/4885 |
| US-11905295-B2 | Solid forms of tabernanthalog monofumarate salt for treating neurological disorders and/or psychiatric disorders | FAH, SLC6A3, SLC6A2 | DRD2 2293/4885MEN1 1569/4885HTR2A 736/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.